BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30186820)

  • 1. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.
    Kunovsky L; Tesarikova P; Kala Z; Kroupa R; Kysela P; Dolina J; Trna J
    Can J Gastroenterol Hepatol; 2018; 2018():5389820. PubMed ID: 30186820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in pancreatic cancer research: moving towards early detection.
    He XY; Yuan YZ
    World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
    Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
    Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study.
    Gao H; Liu T; Wang G; Gao Y; Yin L; Peng Y; Lyu N; Zhang K; Gao W; Wu J; Jiang K; Wei J; Miao Y
    Langenbecks Arch Surg; 2019 Mar; 404(2):175-182. PubMed ID: 30826926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
    Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
    World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center.
    Hsu CP; Hsu JT; Liao CH; Kang SC; Lin BC; Hsu YP; Yeh CN; Yeh TS; Hwang TL
    Asian J Surg; 2018 Mar; 41(2):115-123. PubMed ID: 28010955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study.
    Kimura H; Ohtsuka T; Matsunaga T; Watanabe Y; Tamura K; Ideno N; Aso T; Miyazaki T; Osoegawa T; Aishima S; Miyasaka Y; Ueda J; Ushijima Y; Igarashi H; Ito T; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Oct; 44(7):1148-54. PubMed ID: 26284536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma.
    Arima K; Yamashita YI; Hashimoto D; Nakagawa S; Umezaki N; Yamao T; Tsukamoto M; Kitano Y; Yamamura K; Miyata T; Okabe H; Ishimoto T; Imai K; Chikamoto A; Baba H
    Am J Surg; 2018 Jul; 216(1):111-115. PubMed ID: 28859917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystic pancreatic tumors: diagnostics and new biomarkers].
    Berger AW; Seufferlein T; Kleger A
    Chirurg; 2017 Nov; 88(11):905-912. PubMed ID: 28831506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma.
    Lee W; Yoon YS; Han HS; Cho JY; Choi Y; Jang JY; Choi H
    J Surg Oncol; 2016 Feb; 113(2):203-8. PubMed ID: 26799261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.